How Is Cellular Therapy Changing Care for Hematologic Malignancies?

By The Fellow on Call - Last Updated: October 10, 2023

In this episode of “The Fellow on Call,” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; focus on cellular therapies for hematologic malignancies.

They highlight the latest research on chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and autologous hematopoietic stem cell transplantation (AHSCT). The hosts discuss key considerations surrounding CAR-T, including the manufacturing process, commercial CAR-T, as well as side effects and adverse events associated with CAR-T.

They also discuss the latest information on bispecific antibodies and how they fit into the treatment paradigm. Additionally, they speak about the role of AHSCT in lymphoma.

This podcast originally appeared on thefellowoncall.com.

How to Approach Relapsed DLBCL After CAR-T Therapy

What to Know About Relapsed Disease Treatment After 12 Months in DLBCL

How to Approach Patients with Primary Refractory DLBCL

How Has Treatment for Advanced DLBCL Evolved?

What Does the Latest Research Say About Managing DLBCL?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

How Is Cellular Therapy Changing Care for Hematologic Malignancies?

Related